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Abstract. In the current context of the pandemic triggered by 
SARS-cOV-2, the immunization of the population through 
vaccination is recognized as a public health priority. In the case 
of SARS-cOV-2, the genetic sequencing was done quickly, 
in one month. Since then, worldwide research has focused 
on obtaining a vaccine. This has a major economic impact 
because new technological platforms and advanced genetic 
engineering procedures are required to obtain a cOVId-19 
vaccine. The most difficult scientific challenge for this future 
vaccine obtained in the laboratory is the proof of clinical 
safety and efficacy. The biggest challenge of manufacturing 
is the construction and validation of production platforms 
capable of making the vaccine on a large scale.
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1. Introduction
In December 2019, the first patient with an atypical form of 
pneumonia was diagnosed in china, a disease that would later 
be referred to as cOVId-19 by the World Health Organization 
(WHO). One month later, in January 2020, the causative agent 
of the cOVId-19 disease, the SARS-cOV-2 virus, was deci-
phered and identified and its genome was published rapidly (1).
By mid-April, 2020, the extent of impact of cOVId-19 
on the global population was becoming evident. The most 
adversely affected region per capita was Western Europe, the 
most seriously affected population being the elderly, especially 
those with extensive co-morbidities and weakened immune 
systems. The causes for regional differences in cOVId-19 
will require months of analysis, if not years, to ascertain. More 
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focused approaches to reduce the impacts of cOVId-19 in 
the near-term, especially on the most vulnerable populations, 
need to be pursued, in parallel with longer-term approaches to 
lessen the impact of cOVId-19 (or other coronavirus-driven 
diseases) across all demographics.
As of mid-April, the very short-term measures that have 
been implemented to reduce the transmission of SARS-coV-2 
are the same as those that were taken to reduce the transmission 
of SARS-coV during the 2002-2003 SARS pandemic: good 
hygiene and quarantine, with the latter being far more severe 
and extensive than the quarantine implemented in 2002-2003. 
Other short-term measures that have been implemented 
on a very sporadic basis are what can be termed ‘tactical 
treatments’. These tactical treatments do not strengthen the 
immune system, but rather have the goal of containing the 
adverse impacts of the viral attack. Some examples of tactical 
treatments that have been tested are EIdd-2801, remdesivir, 
favipiravir, chloroquine, hydroxychloroquine, combination of 
lopinavir and ritonavir, tocilizumab, losartan, to name a few. 
Tests so far have yielded very mixed results.
A second avenue being pursued to ameliorate/reduce the 
effects of cOVId-19 is development of vaccines to induce 
viral immunity. The bulk of the present review addresses the 
status and prospects of this vaccine approach.
The third leg of this triad of approaches to ameliorate 
the ravaging effects (especially for the most vulnerable) of 
cOVId-19 is what can be called the ‘strategic treatment’ 
approach (2). This approach has the goal of strengthening the 
immune system to allow its adaptive component to neutralize 
the incoming coronavirus without the need for external 
support. Strategic treatments eliminate tangible factors that 
contribute to weaken the immune system. Some examples 
of such factors, based on existing studies, include titanium 
dioxide, air pollution, chlorpyrifos, aluminum sulfate, prenatal 
alcohol exposure, ZnO, oil fly ash, and many others (3‑9). 
Also the real life exposure scenario in which we are exposed 
continuously to combination of stressors influences in the long 
term the immune system and the response of the organism to 
the viral stressors (10-14).
Tsatsakis et al (15) have shown how pollutants can influ-
ence the immune system particularly by modulating AhR 
pathway and how these effects can be prevented by more strict 
regulations. While some positive impact may result in the 
short-term from strategic treatments, their main impact will 
probably be for the long-term, except for those whose immune 
systems have suffered irreversible damage or those who have 
an overwhelming genetic predisposition to immune dysfunc-
tion. Because strategic treatments appropriate to any specific 
individual are difficult to identify, and difficult to eliminate 
because of ingrained habits, some emphasis needs to be placed 
on those types of treatments that do not require severe lifestyle 
alterations.
This work aims to analyze the strategies and challenges 
regarding the development of effective vaccines against 
SARS-cOV-2. The discovery of a vaccine against the novel 
coronavirus is an important component of the three-pronged 
approach described initially, given that the pandemic cannot 
seem to be entirely stopped by social distancing and good 
hygiene practices. The tactical therapies identified so far have 
not been entirely effective, especially for the most vulnerable 
individuals, being unable to prevent severe disability and 
ultimately death. While healthcare systems are still struggling 
not to crumble under pressure from coronavirus patients, 
research laboratories around the world are competing to 
produce an effective vaccine against SARS-coV-2 as soon as 
possible, in order to be able to stop the spread of the new 
coronavirus.
2. Vaccines: an overview
The development of a vaccine is a complex and time-consuming 
process, which differs from the development of conventional 
medicines. Normally, the period of development of a vaccine 
is 12-15 years (16). While the conventional medicines are 
oriented towards the treatment of a disease whose symptoms 
have emerged, vaccines are intended for use in persons not 
yet exhibiting disease symptoms, in order to prevent the 
occurrence of diseases (17). clinical trials to demonstrate the 
effectiveness of a vaccine focus on demonstrating its ability 
to prevent the disease, with minimal adverse reactions in the 
short-term since truly long-term studies in humans are rarely, 
if ever, conducted (especially on the order of decades), which 
implies the need to enroll more people than in traditional drug 
studies (18).
Traditional vaccine development methods, although 
extremely effective in combating highly contagious diseases 
such as measles, require large amounts of viruses or bacteria, 
which can last for months. Those microorganisms then become 
the key element in a vaccine, the so-called antigen, that warns 
the human immune system that some foreign organisms have 
invaded the body and must be eliminated.
Vaccines provide the immune system with the necessary 
instructions for recognizing and mobilizing lines of defense 
against disease-causing microorganisms, such as bacteria or 
viruses. In classical vaccines, antigens (distinctive molecular 
markers) are introduced into the body, originating from 
inactivated or half-active bacteria or attenuated viruses. 
These antigens are capable of causing the disease, but are 
still capable of activating the immune system, and its cells 
develop antibodies. If the person comes in contact with the 
native pathogen, the immune system will already have the 
necessary antibodies ready and will multiply them much 
faster because it has already been sensitized by vaccination.
Risk factors for anti‑SARS‑COV‑2 vaccine efficacy. global 
immune deficiency is a risk factor for anti‑COVID‑19 vaccine 
efficacy, particularly in elderly who have been exposed 
to a myriad of factors that contribute to weakening of the 
immune system, as described previously. These factors also 
result in diseases such as obesity/obesity-related: e.g., type II 
diabetes, metabolic syndrome and immune-mediated cancers. 
Mechanistic reasons for these diseases include weakness of 
antigen recognition, decreased immune cell quantity and 
functionality, increased level/length and timing of humoral 
immune alterations of components, reduced initiation of 
cellular responses, and memory cell disorders. Other associa-
tions with immunodeficiency include age‑dependent humoral 
and immune cell alterations; immunosenescence; malnutri-
tion (19); protein‑energy‑micronutrient deficit and telomere 
shortening (20). In addition, past or current treatments affect 
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the scalable ineffectiveness of vaccines in both older adults (21) 
and children (22), especially in immunocompromised (23).
Exposure to immunosuppressive drugs (24) or residence in 
developing countries (25) with a low socioeconomic status is 
associated with a higher viral mortality compared to residence 
in developed countries (26). current global obesity prevalence 
in adult and children is also a risk factor for anti-SARS-coV-2 
vaccine inefficacy due to higher levels of IL-6 (27) and 
decreased Igg concentrations. Parasitic infections, respira-
tory tract infections such as complicated pneumonia (28), can 
also affect subsequent immune response to anti-SARS-coV-2 
vaccination (29).
Adjuvant purity and safety, knowledge gaps of the relative 
contribution of the innate and adaptive responses to protec-
tion against individual pathogens, and the precise mode of 
action of individual adjuvants (30) are existing negative 
factors in vaccine efficacy. Anti‑SARS‑CoV‑2 vaccines will 
be available by vaccine market players according to current 
orphan drug (31) and vaccine legislation (32,33) due to the 
fight against SARS‑CoV‑2 pandemic. This means that design 
defect, failure to warn, and negligence in testing may also 
affect vaccine efficacy. Under those conditions, long‑term 
safety testing of vaccines in humans will be non-existent. 
There is no data on whether anti-SARS-coV-2 vaccines 
will be first licensed in developed countries (34) or if all 
vaccine production facilities will be adequate to assure a 
reliable supply of new anti-SARS-coV-2 vaccines (35) in a 
timely manner, and are compatible with specifications and 
improved adult vaccine design strategy by WHO or immuno-
biography (36) and heterogeneity of immune responses in the 
elderly subpopulations (36).
Vaccine safety. The safety of the vaccine is initially assessed 
in laboratory studies with mice or rabbits. If the animals do 
not show signs of disease after receiving the vaccine, then the 
tests begin in humans, and the number of subjects gradually 
increases (37). duration of the clinical trial, on average, for a 
classical vaccine (after preclinical stage - in vitro and in vivo 
tests) is as follows (38,39):
In phase I, also called the first human test, the vaccine is 
given to a small group of healthy volunteers (10 to 100). The 
purpose is not to test whether the vaccine protects against the 
disease, but whether it is safe or whether it causes severe side 
effects.
In phase II, the candidate vaccine is administered to a 
larger group of subjects (100-1,000), and in phase III, to an 
even larger group (1,000-100,000). Separate studies may be 
required in adults, children and the elderly. It sometimes 
happens that vaccines that seem safe when given to a small 
number of people, show side effects when given to a larger 
number of people. This is explained by the fact that any 
rare complication is less likely to occur when the group of 
subjects is small. continuous monitoring is important in case 
of complications that occur with delayed effect (40). during 
a pandemic, these sequential studies may be shortened and 
partially overlapped, but it is important that thousands of 
vaccinated people are followed for several months before the 
general purpose vaccine is approved.
If there are more severe signs of inflammation or if the 
vaccine causes the immune system to malfunction in other 
ways, the candidate vaccine may not be suitable for wide-
spread use. When such adverse effects are identified, delays in 
the production process inevitably occur (41). At present, only 
two potential vaccines against the SARS-coV-2 virus are in 
the first phase and this by a derogation from the rule ‑ skipped 
animal studies (Fig. 1).
The first vaccine that does not follow all research steps 
is called mRNA‑1273 and will be tested in the first phase 
in Seattle. There is an explanation for the speed of approval, 
which is related to the fact that the coronavirus is not used in 
the vaccine development. It is an experimental vaccine, made 
by a new method, based on RNA. Basically, the RNA molecule 
in the vaccine teaches the cells to produce the disease‑specific 
antigen and trains the body for the real enemy. But there is 
also a small problem: to date, no vaccine based mRNA tech-
nology has been approved for any disease, although a few have 
reached the second phase of testing (42).
The second vaccine is Ad5-ncoV. The vaccine is created 
by genetic engineering and tries to teach the body to recognize 
the coronavirus protein S, which is delivered via a type-5 
adenovirus. Adenoviruses are a family of about one hundred 
double-stranded dNA viruses that cause various diseases 
in humans and animals, and type-5 is often used for genetic 
recombination.
Although clinical trials have begun for these two candi-
dates and are likely to begin soon for other potential vaccines, 
it is unlikely to move to phase II earlier than a few months.
Vaccine efficacy. Vaccines stimulate immunity to the virus, 
but can also stimulate inflammation in the body. This can 
manifest itself either as pain or inflammation at the site where 
the subject was injected, or as general symptoms such as fever 
or fatigue (symptoms similar to cOVId-19 disease). For most 
vaccines, these reactions are mild and affect only a small 
proportion of subjects.
When a vaccine causes the production of antibodies, in mice 
or in humans, this does not necessarily mean that the vaccine 
will protect against the disease. Ideally, before moving on to 
human studies, researchers should be able to demonstrate that 
Figure 1. Stages of clinical trial for classical vaccine compared with 
cOVId-19 vaccines.
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the vaccine will protect laboratory animals from the disease 
when they are experimentally infected with the virus. In the 
case of diseases caused by previous coronaviruses (SARS and 
MERS), it was difficult to find an animal species that would 
be affected by the disease in the same way as humans are 
affected. However, previous research may help scientists speed 
up the animal testing process for cOVId-19. The protective 
effect of a human vaccine is assessed using a series of studies 
similar to the series of safety studies. If the vaccine elicits an 
immune system response, for example if antibodies can be 
detected in the phase I study, then larger phase II and phase III 
studies can be performed to see if the vaccine protects against 
infection or disease.
Although cOVId-19 is a new disease, research on SARS 
and MERS has helped us understand how the human body 
responds to coronaviruses and how the response of the immune 
system generates protection against disease (43). Restricted 
human studies can also be used to calculate the correct dose 
and schedule for the vaccine. Some vaccines generate a strong 
immune response after a single dose, but others require 
a booster dose after a month or longer. This strategy also 
increases the duration of studies.
To assess whether a vaccine prevents cOVId-19 among 
those exposed to the infection, it should be tested in phase III 
studies, in a setting where the infection is actively occurring. 
In response to the West African Ebola outbreak in 2014/15, the 
rVSV Ebola vaccine went through all three phases of clinical 
development in just 12 months, through the centralized coordi-
nation of WHO, Médecins Sans Frontières. and manufacturer. 
during this period, there were still cases of Ebola in guinea, 
and the protection of the vaccine was demonstrated by vacci-
nating the contacts of the residual cases, as they appeared in 
the community (44).
Vaccine manufacturing. In the case of pandemic vaccines, 
tens or hundreds of millions of doses are needed. This produc-
tion process takes at least six months, if the production lines 
already exist. Any new vaccine involves a new production 
process, which involves several quality control steps.
The manufacturer must ensure that each vaccine produced 
is of consistent quality and requires repeated testing. Moreover, 
because vaccine manufacturing is a biological process, inevi-
tably, some batches of vaccines will fail for reasons that are 
not always clear, which can further delay production. There 
are quite a few manufacturers in the world that can produce 
vaccines on a large enough scale to meet the needs of a 
pandemic.
Vaccine regulation. Before initiating each stage of the human 
testing process, the developer must provide evidence that the 
vaccine has early indications of protection and is safe among 
those who have been tested. Research ethics committees 
review clinical trial plans, and authorities such as the European 
Medicines Agency (EMA) and Food and drug Administration 
(FdA) oversee the entire vaccine development process before 
approving it for general use. These assessments usually take 
several weeks or months (45). Although such approvals could 
be shortened in the event of a pandemic, many potential 
cOVId-19 vaccines use new technologies, so regulators will 
not be able to rely on the experience of similar vaccines to 
speed up the process. developers of the cOVId-19 vaccine 
were given a target to produce a vaccine in 12-18 months, 
while historically, vaccines took 15-20 years to develop. There 
are diseases against which vaccines do not yet exist, despite 
decades of work. For example, more than 100,000 children 
die each year from respiratory diseases caused by another 
RNA virus, RSV (respiratory syncytial virus), which causes 
pneumonia. despite 50 years of research and 18 products 
developed, there is currently no RSV vaccine available (46).
Numerous scientific research groups are working on 
the development of a cOVId-19 vaccine, using a number 
of different approaches. Having many groups in the race is 
important, as most vaccines entering clinical trials will fail for 
safety or efficacy reasons.
3. The development of a COVID‑19 vaccine: current trends 
and prospects
SARS‑COV‑2: a brief summary. SARS-cOV-2 is part of the 
coronavirus family, as is SARS-coV-1 (which generated the 
2003 SARS epidemic) and MERS-coV (which generated the 
MERS epidemic in 2013) (47).
The new SARS-cOV-2 coronavirus (severe acute respira-
tory syndrome coronavirus 2) causes a respiratory infection 
called cOVId-19 (coronavirus infectious disease - 2019), 
with an average incubation period of 5 days (between 2 and 14 
days) (48). The disease is characterized by predominant 
respiratory symptoms (cough, difficulty breathing, fever) of 
moderate intensity in about 80% of cases, but may have severe 
manifestations (bilateral interstitial pneumonia), with progres-
sion to respiratory failure, acute respiratory distress (ARdS), 
the main cause of mortality. There are also cases with gastro-
intestinal manifestations (especially diarrhea), and in some 
patients (especially in the young ones) hypo/anosmia (loss of 
sense of smell) and hypo/dysgeusia (alteration of the sense of 
taste) have been reported as early symptoms (49). 
Shortly after the publication of the genetic structure 
of SARS-cOV-2, the first two vaccines were developed. 
SARS-cOV-2 virus structure is composed of an RNA 
molecule, surrounded by a series of structural and functional 
proteins (50). known structural proteins are protein S (or 
spike - which leads to the characteristic appearance), protein M 
(membrane), protein E (envelopes), protein N (nucleocapsid). 
Of these, protein S has the role of attaching to receptors in 
human cells and facilitating the fusion of viral content with 
the cell. In the case of SARS-cOV-2, the receptor is the angio-
tensin converting enzyme 2 (AcE2), which is found in large 
quantities in the respiratory tract and lung parenchyma (51-54). 
The initial infection of SARS-cOV-2 occurs in the ciliary 
epithelial cells of the bronchi (55,56).
The binding of protein S to AcE2 is greatly favored by 
the existence of the polybase cleavage site - a protein frag-
ment cleaved by the furin enzyme (commonly found in the 
human body), allowing protein S fragments (S1, S2 and S3) to 
perform their function. In addition to fusing the viral envelope 
with the cell membrane, the virus also infects the human cell 
through endocytosis (the cell membrane around the portion 
that binds to the virus forms a vesicle inside the cell, detaches 
from the membrane and introduces the virus into the cell, 
via that vesicle). Through the process of entering the cell, the 
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virus loses its envelope (which fuses with the cell membrane) 
and the viral RNA is free in the cytoplasm, carrying out two 
processes: replication and transcription. First, the cellular 
components responsible for RNA transcription produce viral 
proteins, and the RNA is copied. Subsequently, these proteins 
and copies of the initial RNA are ‘packed’ into new virions, 
released from the cell to spread the infection (57).
Humoral immunity consists of the production of specific 
antibodies against these antigens. These are: i) antibodies 
that appear rapidly during infection and disappear rapidly 
(IgM); and ii) antibodies that appear slower and persist in 
the body for a long time, even after the infection is cured 
(Igg) (58).
cellular immunity requires training certain immune cells 
to recognize and destroy the virus. It has been observed in 
SARS-cOV-2 infection that the number of cd4+ and cd8+ 
T lymphocytes is low in the peripheral blood (because they 
are destroyed in the process of elimination of the virus), but 
has high concentrations of activation markers (59). Regarding 
the SARS-coV virus, memory cells, capable of recognizing 
it, have been identified in the blood of healed patients, several 
years after the infection. The persistence of memory cells is 
an important element to consider in the development of the 
anti-SARS-coV-2 vaccine (60). cases have been described 
where the SARS-coV-2 infection recurs after being considered 
cured (61).
On the other hand, there is evidence that coronaviruses 
are equipped with mechanisms by which they can sometimes 
evade immune attack. First, after infection of the cell, the 
vesicles in which the virus is located are lacking in the recep-
tors that could recognize the virus as an ‘invader’ of the body. 
Second, interferon synthesis (with antiviral function) is inhib-
ited by coronaviruses, and the presentation of viral antigens by 
PcA is low in infected patients (62).
Strategies for COVID‑19 vaccine development. current 
pandemic of cOVId-19, caused by SARS-coV-2, is a global 
epidemiological problem, the solution of which will require 
establishment of large-scale production of the vaccine. given 
the experience of previous coronavirus outbreaks, showing a 
high variability of the virus, it is required to develop a vaccine 
production platform, providing the scalability, technological 
flexibility, and versatility. These vaccines must provide high 
efficacy, safety, and tolerability.
This is due to the time required to prove that the 
proposed vaccine is safe and effective as well as the time 
required to produce millions of doses. Many ‘candidate’ 
vaccines, which initially look promising, are likely to fail 
during the testing process. The process of developing a 
new vaccine begins with a so-called ‘candidate’ vaccine, 
which a team of scientists believes to have potential. 
This is the fastest part of the process and takes up to 
a few weeks. Thus, some candidate vaccines are being 
developed in Russia against cOVId-19. The Shemyakin 
and Ovchinnikov Institute of Bioorganic chemistry is 
developing Liposome-encapsulated dNA-protein vaccine 
based on the cOVId-19 Spike antigens and its dNA coding 
sequence and VLP vaccine based on HSB antigen fused with 
cOVId-19 Spike antigens. The vaccine candidates against 
COVID‑19 based on live attenuated recombinant influenza 
vector platform are developed by FSBSI ‘chumakov 
Federal Scientific Center for Research and Development 
of Immune- and Biological Products of Russian Academy 
of Sciences’ and Smorodintsev Research Institute of 
Influenza (WHO National Influenza Centre). The FSBSI 
‘chumakov Federal Scientific center for Research and 
development of Immune- and Biological Products of 
Russian Academy of Sciences’ is developing two vaccines 
based on an attenuated and an inactivated strain of the 
cOVId-19 virus isolated in centre chumakov (personal 
communication of Professor Egorov).
For efficient application of SARS-coV-2 vaccines, not 
only the production procedure needs to be developed, but 
also requires a large-scale production followed by vaccina-
tion program targeting muti-million population of different 
regions. Only such a complex approach will allow combatting 
of the coronavirus disease pandemic. New technologies do 
not require the work with live virus, making their production 
much easier, but still needing further scientific and techno-
logical evidence (Fig. 2).
Type of vaccines against SARS‑COV‑2
RNA vaccines. The mRNA (encoding RiboNucleic Acid) 
vaccine encodes a stable prefused form (the form before being 
fused to the cell membrane of the host cell) of Spike protein 
(S) (63). Protein complex S is required for membrane fusion 
and host cell infection and has been the target of vaccines 
against MERS and SARS.
Membrane fusion (viral and cellular) is an essential step 
when encapsulated viruses enter cells. Fusion of the double 
lipid layer requires catalysis to overcome a high kinetic barrier, 
and viral fusion proteins are agents that perform this catalytic 
function (64). Although coronavirus uses many different 
proteins to replicate and invade cells, protein S is the main 
surface protein that it uses to bind to a receptor - this becomes 
a bridge to the human cell. After protein S binds to the human 
cell receptor, the viral membrane fuses with the human cell 
Figure 2. Summary of strategy types for cOVId-19 vaccine development. 
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membrane, allowing the viral genome to enter the human cells 
and initiate infection (49).
The mRNA vaccine against SARS-cOV-2 is based on a 
relatively new genetic method that does not require growing 
the virus in the laboratory. The technique transforms the 
human body into a ‘living laboratory’, because the whole 
process is no longer carried out in the laboratory, but directly 
in the body that received the vaccine (65).
The technique is actually based on messenger ribonucleic 
acid (mRNA) fragments, the genetic material that is copied 
from dNA and encodes proteins. Moderna company loads its 
vaccine with viral mRNA, which encodes the proteins of the 
new coronavirus, and then injects it into the body. Immune 
cells from the lymph nodes process the mRNA and synthe-
size specific viral protein antigens so that other immune cells 
recognize them (66). mRNA is like a software molecule in 
the body, which then produces viral proteins that can generate 
an immune response (67). How the body processes the viral 
protein is often very different from the way it processes the 
same protein of the vaccine. Thus, one of the theoretical 
benefits of introducing mRNA into a vaccine is that the body 
causes the viral protein to behave in exactly the same way that 
the virus would have directed the host to do (63) (Table I).
DNA vaccines. dNA vaccines represent the latest direc-
tion of development in the manufacture of vaccines. Vaccines 
obtained by recombinant dNA technology are produced by 
genetic modification.
The dNA encoding the target molecule is introduced via 
a plasmid or viral vector in a suitable microorganism or cell 
line, in which dNA is expressed and translated into protein. 
The product is subsequently recovered by extraction and puri-
fication. The injected DNA is a plasmid plus a promoter that 
provides immunogenic protein synthesis (69).
An advantage of this type of vaccine is that it stimulates 
both humoral and cellular immunity. Also, this type of vaccine 
is stable and does not require maintenance under controlled 
conditions (refrigeration), as is the case for conventional 
vaccines. In contrast to live attenuated vaccines, the risks 
arising from a potential inadequate attenuation of vaccine 
strains are not present in dNA vaccines (70). Other advantages 
of this new technology are the fact that the plasmids used are 
easy to manufacture in large quantities, and the immunity 
conferred is long‑term. The disadvantages identified so far 
with regard to dNA vaccines are due to the fact that this type 
of vaccine is limited to protein immunogens (71).
A clinical trial for a new dNA vaccine against coronavirus 
has begun. This is called chAdOx1 ncoV-19 and it was 
initially developed to prevent MERS (72). This vaccine is 
based on an adenovirus vaccine vector and on SARS-cOV-2 
spike protein (73). It has been modified so that it cannot be 
reproduced in the human body and the genetic code that 
transmits instructions for the production of coronavirus Spike 
protein has been added, allowing the adenovirus to produce 
this protein after vaccination. The result is the formation 
of antibodies against the Spike protein, known to be on the 
surface of SARS-cOV-2 (74).
The INO-4800 vaccine is another new dNA vaccine to 
prevent SARS-cOV-2 infection. It is entering human phase I 
testing (75). The Phase I study will enroll up to 40 healthy 
adult volunteers. Each participant will receive two doses of 
INO-4800 every four weeks, and initial immune responses 
and safety data from the study are expected by the end of 
the summer. Preclinical data have shown promising results 
in immune response in several animal models. Also, the 
preclinical results for the INOVIO SARS-cOV-2 vaccine 
were consistent with the results of the Phase I study for the 
Table I. RNA candidate vaccines approved by WHO as of April 2020 (68).
  current stage of Viruses for which the
candidate vaccine Producer development same strategy was used
LNP-encapsulated mRNA Moderna/NIAId clinical evaluation,  Multiple candidates
  Phase I NcT04283461 
LNP-encapsulated mRNA Fudan University/Shanghai JiaoTong Pre-clinical -
encoding RBd University/RNAcure Biopharma  
   
LNP encapsulated mRNA Fudan University/Shanghai JiaoTong Pre-clinical -
cocktail encoding VLP University/RNAcure Biopharma  
Replicating defective centro Nacional Biotecnología Pre-clinical -
SARS-cOV-2 derived RNAs (cNB-cSIc), Spain  
LNP-encapsulated mRNA University of Tokyo/daiichi-Sankyo Pre-clinical MERS
Liposome-encapsulated mRNA BIOcAd Pre-clinical -
mRNA china cdc/Tongji University/Stermina Pre-clinical -
mRNA Arcturus/duke-NUS Pre-clinical Multiple candidates
mRNA BioNTech/Fosun Pharma/Pfizer Pre‑clinical ‑
saRNA Imperial college London Pre-clinical EBOV, LASV, MARV, 
   Inf (H7N9), RABV
mRNA curevac Pre-clinical RABV, LASV, yFV,
   MERS, InfA, ZIkV
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Middle East Respiratory Syndrome (MERS) vaccine, caused 
by another type of coronavirus. Here, the INOVIO dNA 
vaccine was well tolerated and induced high levels of anti-
body response in 95% of subjects, generating T cell-mediated 
responses in nearly 90% of study participants. Long-term 
antibody response was maintained for up to 60 weeks in the 
case of the anti-MERS vaccine (75) (Table II).
Protein subunit. Subunit vaccines contain only certain 
antigenic determinants of pathogenic microorganisms, and 
are obtained either starting from conventional cultivation 
processes, or by recombinant dNA technology (76).
Antigen determinants included in the vaccine increase the 
efficiency of the immune response, and the presence of a small 
number of pathogens reduces the risk of side effects. Subunit 
vaccines mainly contain surface fragments of pathogens. 
Because these types of structures are weak immunogens, to 
obtain vaccines with suitable efficacy, the antigens are conju-
gated with protein molecules (77).
Antigen purifiers sometimes lead to loss of immunoge-
nicity, requiring coupling with a protein carrier or with an 
aluminum salt. However, adjuvants are associated with the 
onset of local reactions to the vaccination site. Also, the dura-
tion the immunity conferred by vaccination is lower, except for 
live vaccines (78) (Table III).
Viral vectors. Along with traditional virus vaccines, 
viral vectors are widely used, in which genome of one virus 
is used to deliver the antigen of another virus, thus allowing 
development of a platform technology of virus production. 
These technologies are available for large-scale production of 
vaccines. drawbacks of such vaccines include a large variation 
of purification methods, need for a reliable confirmation of 
purity and activity of the virus (79) (Tables IV and V).
VLPs (virus‑like particles). Vaccine development based 
on the recombinant proteins and virus-like particles (VLPs) 
is a more innovative approach. Antiviral vaccines are usually 
developed on the basis of surface proteins that form VLPs. 
Production of VLPs in the cells with further reconstruction 
into the stable and immunogenic forms is a multi-stage 
process. Substantial issues appear for the VLP production 
for non-enveloped viruses. Nucleic acid based vaccines are 
very interesting from the platform technology viewpoint, 
allowing the same process to be used for the production of 
different antigens. They elicit both humoral and cell immune 
responses (80).
Production of these vaccines may be based on E. coli cell 
fermentation and corresponding technologies of extraction and 
purification of plasmids ensuring their structural integrity (81) 
(Table VI).
Inactivated virus. Another category of vaccines is vaccines 
containing whole microorganisms, but inactivated by chemical 
or physical methods. This type of vaccine has the advantage of 
higher stability; however, effectiveness is lower and requires 
reminders of immune system. Vaccines with inactivated live 
virus require stabilization of the structure in the dry form, 
separate supply of the solvent, and cold-chain transportation. 
These factors complicate the production process and lead to 
increase of their cost (82) (Table VII).
Live attenuated virus. Live attenuated vaccines were the 
first vaccines utilized. These types of vaccines are obtained 
through cultivation of microorganisms under suboptimal condi-
tions or through successive passage in cultures, techniques 
that determine attenuation of virulence while maintaining the 
capacity to induce the immune response (83).
Although characterized as very effective, live attenuated 
vaccines have the disadvantages of risks related to the possible 
occurrence of mutations, leading to the virulence reversal, as 
well as contra-indication in the case of immunocompromised 
persons (Table VIII).
Others. The LV-SMENP-dc Vaccine (Lentiviral Minigene 
Vaccine, Shenzhen geno-Immune Medical Institute) entered 
Phase I clinical trial in March 2020. It is a vaccine based on 
dendritic cells modified with a lentiviral vector expressing 
synthetic minigens based on selected viral protein domains, 
and is administered with antigen‑specific cytotoxic T lympho-
cytes (84).
Pathogen‑specific aAPC vaccine (Shenzhen Geno‑Immune 
Medical Institute), Phase 1 clinical trial (85) is based on 
lentiviral vector modified artificial antigen presenting cells 
(aAPcs) expressing synthetic minigens based on selected viral 
protein domains.
Table II. dNA candidate vaccines approved by WHO as of 11 April 2020 (68).
  current stage of Viruses for which the
candidate vaccine Producer development same strategy was used
dNA plasmid vaccine Inovio Pharmaceuticals clinical trial Lassa, Nipah, HIV
Electroporation device  Phase I Filovirus, HPV
  NcT04336410 cancer indications
   Zika, Hepatitis B
dNA plasmid vaccine Zydus cadila Pre-clinical 
dNA with electroporation karolinska Institute/cobra Biologics Pre-clinical 
 (OPENcORONA Project)  
dNA plasmid vaccine Osaka University/Anges/Takara Bio Pre-clinical 
dNA Takis/Applied dNA Sciences/Evvivax Pre-clinical 
Plasmid dNA, Needle-Free delivery Immunomic Therapeutics, Inc./ Pre-clinical SARS
 EpiVax, Inc./PharmaJet, Inc.  
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4. Discussion
The challenges of COVID‑19 vaccines. Where do we stand? 
The development and manufacture of a cOVId-19 vaccine 
is an urgent issue, but it is likely to take many months to 
resolve. Although many companies have announced that the 
COVID‑19 vaccine will be ready soon, this will be quite diffi-
cult to do in reality (72).
The main reason is that before being put on the market, 
the vaccine should be safe, both in the short-term and 
in the long-term. This is very important because, in the 
history of vaccine production, there have been situations of 
Table III. Protein subunit candidate vaccines approved by WHO as of April 2020 (68).
  current stage of Viruses for which the
candidate vaccine Producer development same strategy was used
capsid-like Particle AdaptVac (PREVENT-ncoV consortium) Pre-clinical 
drosophila S2 insect cell expression  Pre-clinical 
system VLPs ExpreS2ion   
drosophila S2 insect cell expression ExpreS2ion Pre-clinical 
system VLPs 
Peptide antigens formulated in lipid IMV Inc Pre-clinical 
nanoparticle formulation  
S protein WRAIR/USAMRIId Pre-clinical 
S protein + Adjuvant National Institute of Infectious Pre‑clinical Influenza
 disease, Japan  
VLP recombinant protein + adjuvant Osaka University/BIkEN/National Pre-clinical 
 Institutes of Biomedical Innovation, Japan  
   
Native‑like trimeric subunit Spike Clover Biopharmaceuticals Inc./ Pre‑clinical HIV, REV Influenza
protein vaccine gSk/dynavax  
Microneedle arrays S1 subunit University of Pittsburgh Pre-clinical MERS
Peptide Vaxil Bio Pre-clinical 
Adjuvanted protein subunit (RBd) Biological E Ltd Pre-clinical 
Peptide Flow Pharma Inc Pre-clinical Ebola, Marburg, HIV, 
   Zika, Influenza, HPV
   therapeutic vaccine, 
   BreastcA vaccine
S protein AJ Vaccines Pre-clinical 
Ii‑Key peptide Generex/EpiVax Pre‑clinical Influenza, HIV,
   SARS-coV
S protein EpiVax/Univ. of georgia Pre-clinical H7N9
S protein (baculovirus production) Sanofi Pasteur Pre‑clinical Influenza, SARS‑CoV
VLPrecombinant protein nanoparticle Novavax Pre-clinical RSV; ccHF, HPV, 
vaccine + Matrix M   VZV, EBOV
gp-96 backbone Heat Biologics/Univ. of Miami Pre-clinical NScLc, HIV, malaria, 
   Zika
Molecular clamp stabilized Spike University of Queensland/GSK/Dynavax Pre‑clinical Nipah, influenza, 
protein   Ebola, Lassa
S1 or RBd protein Baylor college of Medicine Pre-clinical -
Subunit protein, plant produced iBio/cc-Pharming  -
Recombinant protein, nanoparticles Saint‑Petersburg Scientific Research Pre‑clinical ‑
(based on S protein and other epitopes) Institute of Vaccines and Serums  
SARS-cOV-2 xWg-03 truncated S gSk Pre-clinical HPV
(spike) proteins Innovax/xiamen   
University
Adjuvanted microsphere peptide VIdO-InterVac,  Pre-clinical -
 University of Saskatchewan  
Synthetic Long Peptide Vaccine Oncogen Pre-clinical -
candidate for S and M proteins   
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contamination with other viruses, fortunately without major 
consequences (16). For example, one third of the polio vaccines 
administered in the US between 1955 and 1963 also contained 
simian virus 40 (SV40) and more recently, rotavirus vaccines 
have been discovered to also have swine circoviruses (86-88).
In order to avoid such situations, everything to be tested 
on humans should first be checked for purity, and then sterile 
production lines provided. This takes time. In rare cases, 
certain antibodies generated by immunization may promote 
an aggravated form of the disease (a situation called AdE, 
antibody dependent enhancement) (89). When these antibodies 
re-establish contact with the virus, they will actually help it 
enter the cells and cause infection. AdE has been described 
in many viral infections (influenza, Dengue, Zika, etc.), but 
also in coronaviruses. The mechanism of AdE has not been 
confirmed for coronavirus in humans (90).
Several animal studies have shown that some types of 
anti-SARS and anti-MERS vaccines, although effective in 
generating antibodies, can lead to more severe forms of disease 
when the virus is subsequently inoculated (91).
The second reason is that the vaccine must not only be safe, 
but also effective. It must be able to determine the synthesis of 
antibodies of a certain type, at a certain concentration (titer) 
and to provide protection for a reasonable time.
Table IV. Replicating viral vector vaccines approved by WHO as of 11 April 2020 (68).
  current stage of Viruses for which the
candidate vaccine Producer development same strategy was used
Measles Vector Zydus cadila Pre-clinical -
Measles Vector Institute Pasteur/Themis/University of Pre-clinical West nile, chik, Ebola, 
 Pittsburg center for Vaccine Research  Lassa, Zika
Horsepox vector expressing S protein Tonix Pharma/Southern Research Pre-clinical Smallpox, monkeypox
Live viral vectored vaccine based on BiOcAd and IEM Pre-clinical -
attenuated influenza virus backbone
(intranasal)
Influenza vector expressing RBD University of Hong Kong Pre‑clinical ‑
VSV vector expressing S protein IAVI/Batavia Pre-clinical Ebola, Marburg, Lassa
Table V. Non-replicating viral vector candidate vaccines approved by WHO as of 11 April 2020 (68).
   Viruses for which the
candidate vaccine Producer current stage of development same strategy was used
Adenovirus type 5 vector canSino Biological Inc/Beijing clinical - Phase I Ebola
(Ad5-ncoV) Institute of Biotechnology chicTR2000031781 
  clinical - Phase II 
  chicTR2000030906 
ChAdOx1 Advent‑IRBM, Pomezia ‑ Italy,  Phase I/II NCT04324606 MERS, influenza, TB,
 and Jenner Institute of the  chikungunya, Zika,
 University of Oxford  MenB, plague
MVA encoded VLP geoVax/BravoVax Pre-clinical LASV, EBOV, MARV, HIV
Ad26 (alone or with  Janssen Pharmaceutical Pre-clinical Ebola, HIV, RSV
MVA boost) companies  
MVA-S encoded dZIF - german center Pre-clinical Many
 for Infection Research  
Adenovirus based NasoVAX Altimmune Pre‑clinical Influenza
expressing SARS2-coV  
spike protein   
Ad5 S (gREVAx™ platform) greffex Pre-clinical MERS
Oral vaccine platform  Vaxart Pre-clinical InfA, cHIkV, LASV,
   NORV, EBOV, RVF,
   HBV, VEE
MVA expressing structural centro Nacional Biotecnología Pre-clinical HIV, HcV, chikungunya,
proteins (cNB-cSIc), Spain  Ebola, zika, malaria,
   leishmania
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However, vaccines never generate immunity to all vacci-
nated people (92). The causes are complex and vary from 
genetic and immunological factors, to the quality of the 
vaccines themselves and how they are administered.
Age is an important aspect and some influenza studies 
have shown that aging of the immune system dramatically 
decreases the effectiveness of vaccination (93). Therefore, for 
any future anti-SARS-cOV-2 vaccine, all these aspects should 
be evaluated, and the primary immunization failures mini-
mized by adjusting the doses or number of administrations.
Assuming that the vaccine will generate an effective 
immune response to a sufficient number of individuals among 
those vaccinated, the time frame of vaccine protection is 
questionable (94). For example, after measles vaccination, a 
small percentage of those who initially respond well, lose their 
protective antibody status within a few years, a phenomenon 
called secondary immunization failure (95).
This is why it takes time to check the post-vaccination 
persistence of anti-cOVId antibodies. Last but not least, both 
safety and efficacy are significantly dependent on the type of 
vaccine, i.e. the technology or platform used.
Some technologies are very new and therefore require 
more careful testing. Others are old but need to be adapted for 
cOVId-19. Another aspect is not only the ability of a company 
to develop the technology, but also its large-scale production 
capacity so that it is quickly accessible globally. Because there 
is no commercially available anti-SARS-cOV-2 vaccine prec-
edent for the proposed platforms, completely new production 
lines, capable of generating billions of doses in a few months, 
must be considered. And this must be done without stopping 
the production of current vaccines, already included in the 
official protocols and guidelines. At present, this capacity will 
be reached with difficulty and will represent an unprecedented 
effort. dNA and RNA vaccines are based on the principle of 
insertion of these nucleic acids in some cells of the vaccinated 
ones, forcing them to make immunogenic viral proteins (96). 
Although some recent data seem encouraging, these concepts 
have questionable efficiency in humans. Non-replicative 
vectors are actually common viruses (e.g., adenovirus) geneti-
cally modified to display SARS‑CoV proteins on the outer 
surface (97). But they are so common that many of us have 
already met with them throughout our lives and as a result, 
we already have immunity and neutralize them before they do 
their job.
The attenuated viruses would be variants of SARS-coV-2 
made less or not at all pathogenic by genetic engineering. They 
are by far the most immunogenic, but there is a risk that they 
will become pathogenic after mutations (98).
Inactivated viruses, viral fragments, and synthetic peptides 
are all relatively weakly immunogenic.
Table VI. VLP (virus like particle) candidates vaccines approved by WHO as of April 2020 (68).
   Viruses for which the
candidate vaccine Producer current stage of development same strategy was used
Virus-like particle, based on Saiba gmbH Pre-clinical Flu, rotavirus, norovirus,
RBd displayed on virus-like particles   West Nile virus, cancer
Plant-derived VLP Medicago Inc. Pre-clinical 
Addomer™ multiepitope display Imophoron Ltd and
 Bristol University's  
 Max Planck centre  
Table VII. Inactivated virus candidate vaccines approved by WHO as of 11 April 2020 (68).
   Viruses for which the
candidate vaccine Producer current stage of development same strategy was used
Inactivated + alum Sinovac Pre-clinical SARS
Inactivated Beijing Institute of Biological Products/ Pre-clinical 
 Wuhan Institute of Biological Products  
TBd Osaka University/BIkEN/NIBIOHN Pre-clinical 
Table VIII. Live attenuated virus candidate vaccines approved by WHO as of 11 April 2020 (68). 
candidate vaccine Producer current stage of development Viruses for which the same strategy was used
deoptimized live codagenix/Serum Pre-clinical HAV, InfA, ZIkV, FMd, SIV, RSV, dENV
attenuated vaccines Institute of India  
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The analysis of these variables is normally done over 10 
years, in the form of a trial. The stages of a trial are inflexible, 
standardized, intensely regulated for the purpose of maximum 
safety and efficacy of the final vaccine.
The first stage is the preclinical research, in which the 
technology that will be included in the vaccine is selected 
and then the efficacy and safety profile of human cells 
(in vitro) and animal models (in vivo) is tested. If the expected 
anti-infectious effect is seen in vitro, and cells do not die 
excessively, then in vivo animal studies are conducted. Mice 
are usually the perfect candidate for in vivo studies, because 
they are about 85% genetically similar to humans, relatively 
inexpensive, and do not raise major ethical issues (99). 
However, one of the notable differences between the human 
and the mouse is fixed in the case of the AcE2 receptor 
gene (to which SARS viruses bind during infection). Mice 
simply do not make the respiratory syndromes, they elimi-
nate the virus relatively quickly from the body. This is why 
it is necessary for either the genetically modified mouse to 
have a human AcE2 receptor, or to use ferrets and monkeys, 
and this makes everything much more expensive and more 
difficult to access.
The preclinical stage lasts between 1½ and 2½ years and is 
by far the most selective. It is estimated that less than 20% of 
the vaccines tested are able to progress to human tests. Some 
fail because the product does not work, others because they 
can no longer find financing (1,100).
After obtaining the vaccine, the first people vaccinated 
will be the highest risk categories. For everyone else, the term 
is sometime in 2022, possibly long after we have naturally 
acquired immunity.
There are still many unknowns related to coronavirus 
immunity and that is why obtaining a vaccine is difficult. 
Future mutations in SARS-cOV-2 could occur at any time, 
which automatically means a high risk of any vaccine 
becoming useless. No vaccine has been obtained for any other 
coronavirus so far, and no one can guarantee its success yet. It 
is possible that we will have the anti-cOVId vaccine in a very 
short time, without having the benefits from long‑term testing 
results. The vaccine will probably not be available to all of us 
for 18 months.
5. Conclusion and future perspectives
Scientists began working on coronavirus vaccines during 
SARS and MERS outbreaks, but their efforts did not materi-
alize because of a myriad of difficulties. Since this extremely 
severe current coronavirus pandemic, cOVId-19, the spread 
of the outbreak appears much broader than was the case for 
SARS. There is also the possibility of the disease becoming 
endemic and seasonal in its appearance, according to some 
investigators. This explains why many research groups and 
companies are undertaking efforts to develop an effective 
vaccine against SARS-coV-2 all over the world, also speeding 
up all the usual phases needed to develop and test a vaccine in 
the human.
An important feature in the landscape of vaccine research 
and development for SARS-cOV-2 is represented by the varied 
range of evaluated technological platforms, including nucleic 
acids (dNA and RNA), virus-like particles, peptides, viral 
vector (replicative and non-replicative), recombinant proteins, 
live attenuated viruses and inactivated viruses. Many of these 
platforms are not currently the basis of vaccines already autho-
rized, but experience in areas such as oncology encourages 
developers to exploit new opportunities for increased develop-
ment and manufacturing speeds.
There is not an effective therapy for severe cOVId-19, 
and social distancing is extremely ‘costly’ from a social 
and economic perspective. Therefore, the development 
of an effective vaccine, along with efforts to implement 
immune-enhancing strategic treatments and shorter-term 
efforts to identify tactical repurposed treatments, should be 
considered major public health priorities. We hope to get 
this key tool for disease prevention, and to do this quite 
soon.
It is unknown whether there ever will be a successful 
SARS-coV-2 vaccine, but the efforts of the scientific 
community in attempting to develop such a vaccine is without 
precedent. Thus, cOVId-19 vaccines are a never ending story.
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